keyword
https://read.qxmd.com/read/38629112/comparing-long-term-outcomes-of-septal-myectomy-and-mitral-valve-replacement-in-hypertrophic-cardiomyopathy-patients-a-retrospective-cohort-study-in-iran
#21
JOURNAL ARTICLE
Aryan Ayati, Mehran Khoshfetrat, Saeed Davoodi, Seyed Hossein Ahmadi Tafti, Reza Arefizadeh
BACKGROUND: Hypertrophic cardiomyopathy (HCM) affects millions of individuals worldwide. In severe cases, it can cause life-threatening conditions such as left ventricular outflow tract (LVOT) obstruction, mitral regurgitation (MR), and sudden cardiac death, making surgical treatment necessary. This study aimed to report the long-term outcomes of HCM patients undergoing septal myectomy or mitral valve replacement (MVR) and compare the results between different types of surgeries. METHODS: This was a retrospective cohort study on HCM patients who underwent surgical treatment in an Iranian referral center between 2005 and 2021...
April 2024: Health Science Reports
https://read.qxmd.com/read/38628440/neuronal-nitric-oxide-synthase-required-for-erythropoietin-modulation-of-heart-function-in-mice
#22
JOURNAL ARTICLE
Jeeyoung Lee, Heather M Rogers, Danielle A Springer, Constance T Noguchi
Introduction: Erythropoietin (EPO) acts primarily in regulating red blood cell production mediated by high EPO receptor (EPOR) expression in erythroid progenitor cells. EPO activity in non-erythroid tissue is evident in mice with EPOR restricted to erythroid tissues (ΔEPORE) that become obese, glucose-intolerant, and insulin-resistant. In animal models, nitric oxide synthase (NOS) contributes to EPO activities including erythropoiesis, neuroprotection, and cardioprotection against ischemia-reperfusion injury...
2024: Frontiers in Physiology
https://read.qxmd.com/read/38627858/implementing-a-clinical-scientist-led-screening-clinic-for-hypertrophic-and-dilated-cardiomyopathies
#23
JOURNAL ARTICLE
Jane Draper, Rachel Bastiaenen, Gerald Carr-White, Teofila Bueser, Jessica Webb, Colin Evans, Soraya Nuthoo, Nabeel Sheikh
BACKGROUND: The burden of screening for inherited cardiac conditions on health services grows ever larger, with each new diagnosis necessitating screening of additional family members. Screening these usually asymptomatic, low-risk individuals is currently performed by consultant cardiologists, consuming vital clinic resources that could otherwise be diverted to sicker patients requiring specialist consultant input. Clinical scientists now constitute a highly skilled and often underutilised group of individuals with training in areas such as clinical evaluation, 12-lead electrocardiography (ECG) interpretation, and echocardiography...
April 17, 2024: Echo Research and Practice
https://read.qxmd.com/read/38625835/management-of-hypertrophic-cardiomyopathy
#24
JOURNAL ARTICLE
Yuhui Zhang, Marianna Adamo, Changhong Zou, Aldostefano Porcari, Daniela Tomasoni, Maddalena Rossi, Marco Merlo, Huihui Liu, Jinxi Wang, Ping Zhou, Marco Metra, Gianfranco Sinagra, Jian Zhang
Hypertrophic cardiomyopathy is an important cause of heart failure and arrhythmias, including sudden death, with a major impact on the healthcare system. Genetic causes and different phenotypes are now increasingly being identified for this condition. In addition, specific medications, such as myosin inhibitors, have been recently shown as potentially able to modify its symptoms, hemodynamic abnormalities and clinical course. Our article aims to provide a comprehensive outline of the epidemiology, diagnosis and treatment of hypertrophic cardiomyopathy in the current era...
April 17, 2024: Journal of Cardiovascular Medicine
https://read.qxmd.com/read/38625808/mavacamten-camzyos-first-in-class-small-molecule-myosin-inhibitor-for-treatment-of-obstructive-hypertrophic-cardiomyopathy
#25
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 2024: Clinical Nurse Specialist CNS
https://read.qxmd.com/read/38625800/mavacamten-camzyos-first-in-class-small-molecule-myosin-inhibitor-for-treatment-of-obstructive-hypertrophic-cardiomyopathy
#26
JOURNAL ARTICLE
Patricia Anne O'Malley
No abstract text is available yet for this article.
May 2024: Clinical Nurse Specialist CNS
https://read.qxmd.com/read/38625395/incremental-value-of-diastolic-wall-strain-in-predicting-heart-failure-events-in-patients-with-atrial-fibrillation
#27
JOURNAL ARTICLE
Naoki Taniguchi, Yoko Miyasaka, Yoshinobu Suwa, Eri Nakai, Shoko Harada, Hiromi Otagaki, Ichiro Shiojima
Diastolic wall strain (DWS), an echocardiographic index based on linear elasticity theory, has been identified as a predictor of heart failure (HF) in patients with sinus rhythm. However, its effectiveness in atrial fibrillation (AF) patients remains uncertain. This study aims to assess DWS as a predictor of HF in AF patients with preserved ejection fraction. We analysed a prospective database of AF patients undergoing transthoracic echocardiography. AF patients with reduced left ventricular ejection fraction (< 50%), posterior wall motion abnormality, hypertrophic cardiomyopathy, valvular heart disease, pericardial disease, congenital heart disease, or history of pacemaker/implantable cardioverter-defibrillator implantation or cardiac surgery were excluded...
April 16, 2024: Heart and Vessels
https://read.qxmd.com/read/38621741/circular-rnas-biogenesis-functions-and-role-in-myocardial-hypertrophy
#28
REVIEW
Natalia M Baulina, Ivan S Kiselev, Olga S Chumakova, Olga O Favorova
Circular RNAs (circRNAs) are a large class of endogenous single-stranded covalently closed RNA molecules. High-throughput RNA sequencing and bioinformatic algorithms have identified thousands of eukaryotic circRNAs characterized by high stability and tissue-specific expression pattern. Recent studies have shown that circRNAs play an important role in the regulation of physiological processes in the norm and in various diseases, including cardiovascular disorders. The review presents current concepts of circRNA biogenesis, structural features, and biological functions, describes the methods of circRNA analysis, and summarizes the results of studies on the role of circRNAs in the pathogenesis of hypertrophic cardiomyopathy, the most common inherited heart disease...
January 2024: Biochemistry. Biokhimii︠a︡
https://read.qxmd.com/read/38621499/incidence-of-newly-recognized-atrial-fibrillation-in-patients-with-obstructive-hypertrophic-cardiomyopathy-treated-with-mavacamten
#29
JOURNAL ARTICLE
Matteo Castrichini, Said Alsidawi, Jeffrey B Geske, Darrell B Newman, Adelaide M Arruda-Olson, J Martijn Bos, Steve R Ommen, Konstantinos C Siontis, Michael J Ackerman, John R Giudicessi
No abstract text is available yet for this article.
April 13, 2024: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://read.qxmd.com/read/38616285/carnitine-palmitoyltransferase-ii-cpt-ii-deficiency-responsible-for-refractory-cardiac-arrhythmias-acute-multiorgan-failure-and-early-fatal-outcome
#30
JOURNAL ARTICLE
Gregorio Serra, Vincenzo Antona, Vincenzo Insinga, Giusy Morgante, Alessia Vassallo, Simona La Placa, Ettore Piro, Sergio Salerno, Ingrid Anne Mandy Schierz, Eloisa Gitto, Mario Giuffrè, Giovanni Corsello
BACKGROUND: Carnitine palmitoyltransferase II (CPT II) deficiency is a rare inborn error of mitochondrial fatty acid metabolism with autosomal recessive pattern of inheritance. Its phenotype is highly variable (neonatal, infantile, and adult onset) on the base of mutations of the CPT II gene. In affected subjects, long-chain acylcarnitines cannot be subdivided into carnitine and acyl-CoA, leading to their toxic accumulation in different organs. Neonatal form is the most severe, and all the reported patients died within a few days to 6 months after birth...
April 14, 2024: Italian Journal of Pediatrics
https://read.qxmd.com/read/38615672/association-between-hypertrophic-cardiomyopathy-and-variations-in-sarcomere-gene-and-calcium-channel-gene-in-adults
#31
JOURNAL ARTICLE
Jia Zhao, Bo Wang, Shengjun Ta, Xiaonan Lu, Xueli Zhao, Jiao Liu, Jiarui Yuan, Jing Wang, Liwen Liu
INTRODUCTION: Calcium channel gene variations have been reported to be associated with hypertrophic cardiomyopathy (HCM) in family, but the relationship between calcium channel gene variations and HCM remains undefined in population. METHODS: A total of 719 HCM unrelated patients were initially enrolled. Finally, 371 patients were identified based on inclusion and exclusion criteria, including 145 patients with gene negative, 28 patients with a single rare calcium channel gene variation (calcium gene variation), 162 patients with a single pathogenic/likely pathogenic sarcomere gene variation (sarcomere gene variation) and 36 patients with a single pathogenic/likely pathogenic sarcomere gene variation and a single rare calcium channel gene variation (double gene variations)...
April 12, 2024: Cardiology
https://read.qxmd.com/read/38615019/transapical-intramyocardial-septal-microwave-ablation-in-treatment-of-hypertrophic-obstructive-cardiomyopathy-12-month-outcomes-of-a-swine-model
#32
JOURNAL ARTICLE
Mi Zhou, Zhaolong Li, Yun Liu, Yuehua Fang, Le Qin, Wenjie Yang, Fuhua Yan, Qiang Zhao
BACKGROUND: To date, the extended Morrow procedure is considered the gold standard treatment for patients with obstructive hypertrophic cardiomyopathy who experience severe symptoms and are unresponsive to medication treatment. We therefore aimed to perform transapical intramyocardial septal microwave ablation to reduce the thickness of the interventricular septum myocardium in a minimally invasive method. METHODS: Fourteen swine were divided to form either a microwave ablation group (n = 7) or a sham group (n = 7)...
April 13, 2024: Journal of Cardiothoracic Surgery
https://read.qxmd.com/read/38614801/treatment-of-hypercalcaemia-of-malignancy-in-adults
#33
JOURNAL ARTICLE
Darran Mc Donald, Matthew T Drake, Rachel K Crowley
Hypercalcaemia of malignancy (HCM) is a common metabolic complication of advanced malignancies with a prevalence varying from 2-30%, depending on cancer type and disease stage. HCM is associated with impaired quality of life, increased risk of hospitalisation and limited survival. Evidence-based guidelines for management of HCM have been lacking to date, despite its prevalence and detrimental impact. This concise guidance highlights key recommendations from the recent Endocrine Society Clinical Practice Guidelines on Treatment of Hypercalcaemia of Malignancy in Adults, published in December 2022...
September 2023: Clinical Medicine: Journal of the Royal College of Physicians of London
https://read.qxmd.com/read/38614650/the-weight-of-obesity-in-hypertrophic-cardiomyopathy
#34
JOURNAL ARTICLE
Marina Zaromytidou, Konstantinos Savvatis
Hypertrophic cardiomyopathy is one of the most frequently diagnosed primary conditions of the heart muscle. It is considered to be inherited, caused by genetic mutations encoding for sarcomere proteins. The marked heterogeneity in clinical manifestations and natural course of the disease, even among family members sharing the same genetic mutation, has raised the question of non-genetic environmental factors contributing to the phenotype. Obesity has been associated with worse cardiovascular outcomes in the general population...
July 2023: Clinical Medicine: Journal of the Royal College of Physicians of London
https://read.qxmd.com/read/38612980/short-communication-taurine-long-term-treatment-prevents-the-development-of-cardiac-hypertrophy-and-premature-death-in-hereditary-cardiomyopathy-of-the-hamster-is-sex-independent
#35
JOURNAL ARTICLE
Ghassan Bkaily, Yanick Simon, Joe Abou Abdallah, Chaimaa Ouertane, Amina Essalhi, Abdelouahed Khalil, Danielle Jacques
Recently, we reported that during the hypertrophic phase (230 days old) of hereditary cardiomyopathy of the hamster (HCMH), short-term treatment (20 days) with 250 mg/kg/day of taurine prevents the development of hypertrophy in males but not in females. However, the mortality rate in non-treated animals was higher in females than in males. To verify whether the sex-dependency effect of taurine is due to the difference in the disease's progression, we treated the 230-day-old animals for a longer time period of 122 days...
March 26, 2024: Nutrients
https://read.qxmd.com/read/38606381/case-report-multiple-types-of-arrhythmias-in-a-late-confirmed-danon-disease
#36
Nan Wang, Yu Cao, Jie Wang, Qing Zhang
INTRODUCTION: Danon disease is an X-linked disorder caused by pathogenic variants in lysosome-associated membrane protein 2 ( LAMP2 ) gene, typically characterized by the triad of hypertrophic cardiomyopathy, myopathy, and intellectual disability. However, many patients may not present the typical presentation, especially in the early stage. Electrocardiogram (ECG) abnormalities can be found in almost all patients, with Wolff-Parkinson-White (WPW) syndrome being the most common. We reported the case of a 51-year-old woman who experienced multiple types of arrhythmias over three decades and was diagnosed with Danon disease late by genetic testing...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38602080/innovation-in-surgical-treatment-of-hypertrophic-obstructive-cardiomyopathy-in-children
#37
REVIEW
Zhangwei Wang, Kai Ma, Yaobin Zhu, Shoujun Li
Hypertrophic cardiomyopathy is the second most common cardiomyopathy affecting children and adolescents and is the main cause of sudden death of young athletes. The natural prognosis of children with severe hypertrophic obstructive cardiomyopathy is not optimistic, and it is not uncommon for children with hypertrophic obstructive cardiomyopathy who do not respond to medication. Surgical treatment is often the only solution. Conventional surgical methods in the past include classic or modified extended Morrow operation, classic or modified Konno operation, and Ross-Konno operation...
April 11, 2024: Cardiology in the Young
https://read.qxmd.com/read/38601847/ventricular-tachycardia-ablation-through-a-recanalized-surgically-plicated-left-ventricular-apical-aneurysm
#38
Michael Freilich, Daniel R Musikantow, Srinivas Dukkipati
Left ventricular apical aneurysms are associated with scar-related ventricular tachycardia (VT) in hypertrophic cardiomyopathy patients. We present a patient with apical hypertrophic cardiomyopathy who underwent combined epicardial and endocardial VT ablation of a left ventricular apical aneurysm, necessitating repeat endocardial VT ablation through a recanalized surgical plication.
May 15, 2024: JACC. Case reports
https://read.qxmd.com/read/38599256/safety-and-efficacy-of-metabolic-modulation-with-ninerafaxstat-in-patients-with-nonobstructive-hypertrophic-cardiomyopathy
#39
JOURNAL ARTICLE
Martin S Maron, Masliza Mahmod, Azlan Helmy Abd Samat, Lubna Choudhury, Daniele Massera, Dermot M J Phelan, Sharon Cresci, Matthew W Martinez, Ahmad Masri, Theodore P Abraham, Eric Adler, Omar Wever-Pinzon, Sherif F Nagueh, Gregory D Lewis, Paul Chamberlin, Jai Patel, Arash Yavari, Hakim-Moulay Dehbi, Rizwan Sarwar, Betty Raman, Ladislav Valkovič, Stefan Neubauer, James E Udelson, Hugh Watkins
BACKGROUND: In nonobstructive hypertrophic cardiomyopathy (nHCM), there are no approved medical therapies. Impaired myocardial energetics is a potential cause of symptoms and exercise limitation. Ninerafaxstat, a novel cardiac mitotrope, enhances cardiac energetics. OBJECTIVES: To evaluate the safety and efficacy of ninerafaxstat in nHCM. METHODS: Patients with HCM and left ventricular (LV) outflow gradient <30 mmHg, ejection fraction ≥50% and peak VO2 <80% predicted, were randomized to ninerafaxstat 200 mg BID or placebo (1:1) for 12 weeks...
April 1, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38599198/the-role-of-angiotensin-ii-receptor-blockers-in-the-management-of-hypertrophic-cardiomyopathy-an-updated-meta-analysis-of-randomized-controlled-trials
#40
Yong Wan, Shuai He, Tingli Xu, Shuwei Wang, Minfang Qi, Pengcheng Gan
INTRODUCTION: The use of angiotensin II receptor blockers (ARBs) in the treatment of hypertrophic cardiomyopathy (HCM) remains a subject of controversy. METHODS: We conducted a comprehensive search of the Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases until October 2023 to identify articles investigating the effects of ARBs in patients diagnosed with HCM. Predefined criteria were utilized for selecting data on study characteristics and results...
April 10, 2024: Cardiology
keyword
keyword
12994
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.